Health ❯Pharmaceuticals ❯Drug Development ❯Cancer Treatment
The German pharmaceutical giant adjusts its guidance due to US tariffs and currency volatility but remains optimistic about growth, bolstered by a strategic acquisition of SpringWorks Therapeutics.
